SKYE on Nasdaq

Skye Bioscience, Inc.

Skye Bioscience, Inc. is a clinical-stage biotechnology company pioneering next-generation molecules that modulate G-protein-coupled receptors ("GPCRs") to treat obesity, overweight, and metabolic.3 From its latest annual report

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with another stock.

  • TickerSKYE on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersSan Diego, California1
  • Incorporated inNV2
  • Business address11250 El Camino Real, Suite 100, San Diego, Ca 921302
  • Filer categoryNon-accelerated filer, Smaller reporting company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Skye Bioscience, Inc. is a clinical-stage biotechnology company pioneering next-generation molecules that modulate G-protein-coupled receptors ("GPCRs") to treat obesity, overweight, and metabolic disorders. Our lead candidate, nimacimab, is a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 ("CB1")—a key GPCR involved in metabolic regulation.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income456789-$58.2M in 2025+777% since 2019
-$60.0M-$40.0M-$20.0M02019: -$6.6M-$6.6M20192020: -$6.3M-$6.3M2020−5%2021: -$7.8M-$7.8M2021+25%2022: -$18.3M-$18.3M2022+133%2023: -$34.7M-$34.7M2023+90%2024: -$30.2M-$30.2M2024−13%2025: -$58.2M-$58.2M2025+93%
Net income456789-$55.9M in 2025
-$60.0M-$40.0M-$20.0M0$20.0M2019: $1.1M$1.1M20192020: -$6.6M-$6.6M20202021: -$8.5M-$8.5M2021+30%2022: -$19.5M-$19.5M2022+129%2023: -$37.6M-$37.6M2023+93%2024: -$26.6M-$26.6M2024−29%2025: -$55.9M-$55.9M2025+111%

Every line of the income statement as filed: the last 2 fiscal years, latest first.9

Period ending2025-12-312024-12-31
Research and development$42.4M$18.7M
General and administrative$15.8M$17.7M
Change in estimate for legal contingencies$0-$4.2M
Income from insurance recovery$0-$2.0M
Total operating expenses$58.2M$30.2M
Operating loss-$58.2M-$30.2M
Interest expense$0$749.3K
Interest income$1.9M$3.0M
Gain from asset sale-$360.8K-$1.4M
Other expense$502$2.2K
Total other (income) expense, net-$2.2M-$3.6M
Loss before income taxes-$55.9M-$26.6M
Provision for income taxes$5.4K$10.1K
Net loss-$55.9M-$26.6M
Basic (in dollars per share)-$1.41-$0.73
Diluted (in dollars per share)-$1.41-$0.73
Basic (in shares)39.7M shares36.5M shares
Diluted (in shares)39.7M shares36.5M shares

Compare Skye Bioscience, Inc. with another company

Leadership

Who has led Skye Bioscience, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Yosbani Mendez2014
  2. John B. Hollister2014
  3. Punit Dhillon2020–now

Chair

  1. Cosmas N. Lykos2014–2018

Chief financial officer

  1. Yosbani Mendez2014
  2. Elizabeth Berecz2014–2018
  3. Douglas A. Cesario2018
  4. Elena Traistaru2020
  5. Kaitlyn Melanie Arsenault2021–2026
  6. John P. Sharp2026–now

Chief operating officer

  1. Tuan Tu Diep2026–now
201520202025
Board members and other officers (22)

Former names

  • Emerald Bioscience, Inc.Mar 25, 2019 to Jan 7, 20212
  • Nemus Bioscience, Inc.Nov 3, 2014 to Mar 14, 20192
  • LOAD GUARD LOGISTICS, INC.Nov 8, 2012 to Oct 30, 20142
  • LOAD GUARD TRANSPORTATION, INC.Mar 25, 2011 to Nov 7, 20122

Timeline

  1. Aug 11, 2020New chief executive Punit Dhillon becomes CEO12
  2. Nov 10, 2014New chief executive John B. Hollister becomes CEO14
  3. Jan 29, 2014New chief executive Yosbani Mendez becomes CEO13

Filings

275 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 56 major events, 119 insider forms, 20 large holders, 3 private raises, 57 other. The latest 20:

  1. Oct 14, 2026SCHEDULE 13G EDGAR
  2. Sep 24, 2026SCHEDULE 13D/A EDGAR
  3. Sep 24, 20264 EDGAR
  4. Sep 24, 20264 EDGAR
  5. Sep 18, 20264 EDGAR
  6. Sep 18, 20264 EDGAR
  7. Sep 11, 2026DEFA14A EDGAR
  8. Sep 11, 20268-K EDGAR
  9. Aug 24, 2026DEFA14A EDGAR
  10. Aug 24, 20268-K EDGAR
  11. Aug 20, 2026DEFA14A EDGAR
  12. Aug 20, 20268-K/A EDGAR
  13. Aug 20, 20264 EDGAR
  14. Aug 20, 20264 EDGAR
  15. Aug 19, 2026DEFA14A EDGAR
  16. Aug 19, 20268-K EDGAR
  17. Aug 18, 2026SCHEDULE 13D/A EDGAR
  18. Aug 14, 2026DEFA14A EDGAR
  19. Aug 14, 202610-Q EDGAR
  20. Aug 14, 20268-K EDGAR

The 275 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

34 open-market trades by officers, directors and large owners since October 2021: 4 buys and 30 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 23, 2026Schwab Andrew J.DirectorSale119,379$1.61$192.2KForm 4
Sep 23, 20265AM Ventures II LP10% ownerSale119,379$1.61$192.2KForm 4
Sep 22, 2026Schwab Andrew J.DirectorSale28,700$1.65$47.4KForm 4
Sep 22, 20265AM Ventures II LP10% ownerSale28,700$1.65$47.4KForm 4
Sep 16, 2026Schwab Andrew J.DirectorSale33,892$1.91$64.7KForm 4
Sep 16, 2026PARMAR KUSH10% ownerSale33,892$1.91$64.7KForm 4
Aug 20, 2026Schwab Andrew J.DirectorSale7,700$0.32$2.5KForm 4
Aug 20, 20265AM Partners II, LLC10% ownerSale7,700$0.32$2.5KForm 4
Aug 19, 2026Schwab Andrew J.DirectorSale68,140$0.35$23.8KForm 4
Aug 19, 20265AM Partners II, LLC10% ownerSale68,140$0.35$23.8KForm 4
Aug 18, 2026Schwab Andrew J.DirectorSale300,000$0.38$114.0KForm 4
Aug 18, 20265AM Partners II, LLC10% ownerSale300,000$0.38$114.0KForm 4
Aug 22, 2025Schwab Andrew J.DirectorSale170,449$3.42$582.9KForm 4
Aug 22, 2025ROCKLAGE SCOTT M10% ownerSale170,449$3.42$582.9KForm 4
Aug 21, 2025Schwab Andrew J.DirectorSale60,956$3.57$217.6KForm 4
Aug 21, 2025ROCKLAGE SCOTT M10% ownerSale60,956$3.57$217.6KForm 4
Nov 18, 2024ARSENAULT KAITLYNChief Financial OfficerSale43,026$4.99$214.7KForm 4
Nov 18, 2024Diep Tuan TuChief Operating OfficerSale19,489$4.99$97.2KForm 4
Nov 18, 2024ARSENAULT KAITLYNChief Financial OfficerSale43,206$4.99$215.6KForm 4
Nov 18, 2024DHILLON PUNITChief Executive OfficerSale82,546$4.99$411.9KForm 4

All 34 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Mar 13, 2024Raised $40 million in a private offering of equity Form D: 13 investors so far Form D
  2. Jan 31, 2024Raised $50 million in a private offering of equity Form D: 11 investors so far Form D
  3. Aug 15, 2023Raised $62.3 million in a private offering of securities Form D: 12 investors so far Form D

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49